Jefferies Downgrades Ampio Pharmaceuticals To Hold
Analysts at Jefferies downgraded Ampio Pharmaceuticals (NYSE: AMPE) from Buy to Hold.
The target price for Ampio Pharmaceuticals has been lowered from $14 to $5.
Ampio Pharmaceuticals shares have fallen 15.02% over the past 52 weeks, while the S&P 500 index has surged 19.77% in the same period.
Ampio Pharmaceuticals' shares rose 0.71% to $5.70 in pre-market trading.
Latest Ratings for AMPE
|Jun 2014||Jefferies||Initiates Coverage on||Buy|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.